المؤلفون: Eleonora De Maio, Gabrielle Selmes, Slimane Zerdoud, Eva Jouve, R. Aziza, Jean-Louis Lacaze, Ciprian Chira, F. Izar, Florence Dalenc, C. Massabeau, Mony Ung, Anne Pradines

المصدر: Breast, Vol 59, Iss, Pp 144-156 (2021)
The Breast : Official Journal of the European Society of Mastology

مصطلحات موضوعية: Oncology, Review, NA, not applicable, Circulating Tumor DNA, law.invention, Circulating tumor cell, Randomized controlled trial, law, Epidemiology, HER2, human epidermal growth factor receptor 2, ctDNA, circulating tumor DNA, RC254-282, Curative intent, Incidence (epidemiology), Incidence, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, General Medicine, CTCs, circulating tumor cells, Neoplastic Cells, Circulating, Observational Studies as Topic, CT scan, Computed Tomography scan, 18F-FDG-PET/CT, Positron Emission Tomography/Computed Tomography with 18fluorodeoxyglucose, Female, CTCs, Cohort study, medicine.medical_specialty, 18F-FES, 16α-[18F]-Fluoro- 17β-estradiol, Breast Neoplasms, MRI, Magnetic Resonance Imaging, OMD, oligometastatic disease, OS, overall survival, MBC, Metastatic Breast Cancer, Breast cancer, Internal medicine, RFS, relapse-free survival, Biomarkers, Tumor, medicine, Humans, OMBC, oligometastatic breast cancer, Oligometastatic breast cancer, Biology, business.industry, HR, hormone receptor, Definition, medicine.disease, WB-MRI, Whole-body MRI, MicroRNAs, NED, No Evidence of Disease, SBR grade, Scarf-Bloom-Richardson grade, SBRT, Stereotactic Body Radiotherapy, Surgery, Observational study, Observatory, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b69d7d75860baca5664d0f6f4d7d4a88Test
http://www.sciencedirect.com/science/article/pii/S0960977621004069Test

المؤلفون: Tsutomu Iwasa, Tsuyoshi Saito, Kosuke Kashiwabara, Eiko Sakata, Hirofumi Mukai, Masahiro Kitada, Tomohiko Aihara, Naruto Taira, Junji Tsurutani, Yuichiro Kikawa, Tsutomu Takashima, Masato Takahashi, Fumikata Hara, Yoichi Naito, Hiroaki Kato, Yoshie Hasegawa

المصدر: Breast, Vol 55, Iss, Pp 63-68 (2021)
The Breast : Official Journal of the European Society of Mastology

مصطلحات موضوعية: TTF, time-to-treatment failure, MBC, metastatic breast cancer, Phases of clinical research, DFI, disease-free interval, Gastroenterology, law.invention, 0302 clinical medicine, PR, partial response, Nanoparticle albumin–bound paclitaxel, Randomized controlled trial, Nab-PTX, nanoparticle albumin–bound paclitaxel, law, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, 030212 general & internal medicine, Chemotherapy-induced peripheral neuropathy, Hazard ratio, CIPN, chemotherapy-induced peripheral neuropathy, General Medicine, Metastatic breast cancer, Solvent-base paclitaxel, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, PFS, progression-free survival, Treatment Outcome, RDI, relative dose intensity, 030220 oncology & carcinogenesis, Toxicity, Original Article, Female, ORR, overall response rate, DCR, disease control rate, medicine.medical_specialty, Paclitaxel, Breast Neoplasms, Nab-paclitaxel, lcsh:RC254-282, TNBC, triple-negative breast cancer, Drug Administration Schedule, PROs/HRQoL, patient-reported outcomes/health-related quality-of-life, ECOG, Eastern Cooperative Oncology Group performance, OS, overall survival, 03 medical and health sciences, Internal medicine, Albumins, medicine, Humans, business.industry, QoL, quality-of-life, CR, complete remission, medicine.disease, RECIST, response evaluation criteria in solid tumors, HR, hazard ratio, Confidence interval, CI, confidence interval, sb-PTX, comparing solvent-based paclitaxel, Surgery, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9e8ab9341270c4ff617be8b94a9f0ecTest
http://www.sciencedirect.com/science/article/pii/S0960977620302319Test

المؤلفون: Takahiro Kogawa, Ako Hosono, Kenichi Harano, Ayumi Komuro, Yoichi Naito, Chihiro Kondoh, Kanako Mamishin, Shota Kusuhara, Chikako Funasaka, Toru Mukohara, Takehiro Nakao, Mashiro Okunaka, Toshikatsu Kawasaki, Yoko Fukasawa, Nobuaki Matsubara

المصدر: The Breast : Official Journal of the European Society of Mastology
Breast, Vol 58, Iss, Pp 50-56 (2021)

مصطلحات موضوعية: MBC, metastatic breast cancer, Receptor, ErbB-2, medicine.medical_treatment, AST, aspartate aminotransferase, Gastroenterology, TTF, time to treatment failure, ORR, objective response rate, chemistry.chemical_compound, Paclitaxel plus bevacizumab, 0302 clinical medicine, Breast cancer, Antineoplastic Combined Chemotherapy Protocols, HER2, human epidermal growth factor receptor 2, 030212 general & internal medicine, wPTX, weekly paclitaxel, Lymphangiomatosis, RC254-282, LDH, lactate dehydrogenase, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, General Medicine, Metastatic breast cancer, PS, performance status, Bevacizumab, Treatment Outcome, Paclitaxel, 030220 oncology & carcinogenesis, Female, Original Article, medicine.symptom, AE, adverse event, medicine.drug, DCR, disease control rate, medicine.medical_specialty, Vena Cava, Superior, Breast Neoplasms, SVC, superior vena cava, OS, overall survival, 03 medical and health sciences, Internal medicine, ALT, alanine aminotransferase, medicine, Humans, Chemotherapy, Adverse effect, Retrospective Studies, business.industry, Organ dysfunction, Visceral crisis, BV, bevacizumab, medicine.disease, chemistry, Surgery, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ceeb2f8c28b19a71d25194b192d9cf8fTest
https://pubmed.ncbi.nlm.nih.gov/33901922Test

المؤلفون: Audrey Mailliez, Khalil Saleh, Thierry Petit, Christelle Jouannaud, Etienne Brain, Matthieu Carton, Jean Marc Ferrero, Pierre-Etienne Heudel, Elise Deluche, Marc Debled, Anne Patsouris, Anthony Gonçalves, Lionel Uwer, George Emile, Alexia Savignoni, Florence Dalenc, Marianne Leheurteur, C. Courtinard, Lucie Veron, Marie-Ange Mouret-Reynier, Paul Cottu, Véronique Diéras, Véronique D'Hondt, Suzette Delaloge, Sylvain Ladoire, Mathieu Robain

المساهمون: Institut Gustave Roussy (IGR), Oncologie gynécologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Institut Curie [Paris], Centre Eugène Marquis (CRLCC), Centre Léon Bérard [Lyon], Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), Université Côte d'Azur (UCA)-UNICANCER, Centre Paul Strauss, CRLCC Paul Strauss, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), Institut Bergonié [Bordeaux], Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Jean Godinot [Reims], Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), UNICANCER [Paris], CHU Limoges, Université de Lille-UNICANCER, UNICANCER-Université Côte d'Azur (UCA), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), COLO, Mouniati, Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)

المصدر: Breast
Breast, Elsevier, 2021, 55, pp.16-24. ⟨10.1016/j.breast.2020.11.014⟩
Breast, 2021, 55, pp.16-24. ⟨10.1016/j.breast.2020.11.014⟩
Breast, Vol 55, Iss, Pp 16-24 (2021)
The Breast : Official Journal of the European Society of Mastology

مصطلحات موضوعية: MBC, metastatic breast cancer, BMI, body mass index, [SDV]Life Sciences [q-bio], ESME, Epidemio-Strategy-Medical-Economical, Overweight, Body Mass Index, 0302 clinical medicine, Risk Factors, Medicine, Overall survival, 030212 general & internal medicine, Underweight, TNBC, triple negative breast cancer, ComputingMilieux_MISCELLANEOUS, 2. Zero hunger, General Medicine, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Metastatic breast cancer, 3. Good health, [SDV] Life Sciences [q-bio], 030220 oncology & carcinogenesis, Cohort, Original Article, Female, medicine.symptom, medicine.medical_specialty, BC, breast cancer, Breast Neoplasms, lcsh:RC254-282, OS, overall survival, 03 medical and health sciences, BMI, Breast cancer, Internal medicine, Humans, Obesity, Risk factor, Retrospective Studies, business.industry, HR, hormone receptor, Cancer, nutritional and metabolic diseases, medicine.disease, Surgery, business, Body mass index, PFS, progression free-survival

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24021b6f6a304df99fd5417a240e2abeTest
https://hal.archives-ouvertes.fr/hal-03345238Test

المؤلفون: Giselle A. Suero-Abreu, Timothy Almazan, Shalini R. Krishnasamy, Jae Y. Jung

المصدر: JAAD Case Reports

مصطلحات موضوعية: Oncology, medicine.medical_specialty, TLR7, toll-like receptor 7, MBC, metastatic breast cancer, antitumor immunity, medicine.medical_treatment, synergy, Imiquimod, Cryotherapy, Dermatology, Malignancy, fluorouracil, 030207 dermatology & venereal diseases, 03 medical and health sciences, breast cancer, 0302 clinical medicine, Breast cancer, Internal medicine, cutaneous metastases, medicine, Case Series, in situ vaccination, business.industry, Melanoma, synergy of topical and systemic treatments, medicine.disease, Metastatic breast cancer, imiquimod, 030220 oncology & carcinogenesis, skin-directed treatment, CMOBC, cutaneous metastases of breast cancer, 5FU, fluorouracil 5%, tumor-specific immune response, Topical Fluorouracil, business, cryotherapy, topical treatment, Mastectomy, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3316cab49b2a233fb34948de2f0039aTest
https://doi.org/10.1016/j.jdcr.2018.04.013Test

المؤلفون: Mihaela Palade Gheran, Patricia Calloud de Faudeur, Eti Kimhi, Claudia Altmann-Pospischek, Sabine Spitz, Renate Haidinger, Donatella Decise, Fatima Cardoso, Mona Elzayat, Ana Casas

المصدر: The Breast : official journal of the European Society of Mastology
Breast, Vol 49, Iss, Pp 171-173 (2020)

مصطلحات موضوعية: Isolation (health care), media_common.quotation_subject, Personalized, Advisory Committees, Breast Neoplasms, Disease, ABC, Advanced Breast Cancer, lcsh:RC254-282, 03 medical and health sciences, MBC, Metastatic Breast Cancer, Hope, 0302 clinical medicine, Breast cancer, Nursing, medicine, Humans, 030212 general & internal medicine, skin and connective tissue diseases, Advanced breast cancer (ABC), media_common, Language, Physician-Patient Relations, business.industry, Communication, Social Support, General Medicine, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Metastatic breast cancer, Europe, Feeling, Social Isolation, 030220 oncology & carcinogenesis, Surgery, Original Article, HCP, Healthcare Professional, Female, business, Metastatic breast cancer (MBC)

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::566342df5d5541b4f86b1cfa4d546c81Test
https://hdl.handle.net/10668/14802Test

المؤلفون: Quchang Ouyang, Xin Yi, Xiaohong Yang, Jianxiang Gao, Zheyu Hu, Xuming Hu, Can Tian, Lianpeng Chang, Xuefeng Xia, Yu Tang, Qianjin Liao, Mengjia Xiao, Qiongzhi He, Liping Liu, Hui Wu, Jing Li, Jun Lu, Ning Xie, Huawu Xiao, Min Cao, Zhengrong Shui

المصدر: EBioMedicine
EBioMedicine, Vol 32, Iss, Pp 111-118 (2018)

مصطلحات موضوعية: 0301 basic medicine, Oncology, MBC, metastatic breast cancer, ER, estrogen receptor, Receptor, ErbB-2, Gene mutation pattern, Estrogen receptor, lcsh:Medicine, Drug resistance, SNV, Single nucleotide variants, Gene mutation, medicine.disease_cause, Circulating Tumor DNA, SEER, Surveillance Epidemiology and End Results, AUC, area under the curve, Phosphatidylinositol 3-Kinases, 0302 clinical medicine, HER2, human epidermal growth factor receptor 2, ctDNA, circulating tumor DNA, Indels, insertions and deletions, Neoplasm Metastasis, skin and connective tissue diseases, Triple-negative breast cancer, TNBC, triple negative breast cancer, Mutation, lcsh:R5-920, Mediator Complex, BRCA1 Protein, Progression-free survival, General Medicine, Middle Aged, Metastatic breast cancer, PFS, progression-free survival, Drug Resistance, Multiple, Gene Expression Regulation, Neoplastic, GX, gemcitabine+capecitabine, 030220 oncology & carcinogenesis, Disease Progression, Female, lcsh:Medicine (General), Circulating tumor DNA (ctDNA), WES, whole exome sequencing, IHC, immunohistochemistry, Research Paper, Adult, medicine.medical_specialty, Class I Phosphatidylinositol 3-Kinases, Breast Neoplasms, General Biochemistry, Genetics and Molecular Biology, Disease-Free Survival, 03 medical and health sciences, Internal medicine, medicine, Biomarkers, Tumor, Humans, neoplasms, AI, aromatase inhibitor, Aged, HR/HER2 subtype, TMB, Tumor mutation burden, business.industry, lcsh:R, Cancer, HR, hormone receptor, PR, progesterone receptor, cfDNA, cell-free DNA, medicine.disease, HR, hazard ratio, ROC, receiver operating characteristic, CI, confidence interval, 030104 developmental biology, Drug Resistance, Neoplasm, gDNA, genomic DNA, Tumor Suppressor Protein p53, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09ba2a916d616434f8644bf3d44cb54dTest
http://europepmc.org/articles/PMC6020712Test

المؤلفون: Yuzuru Yamazoe, Maki Tanioka, Kazuhiko Nakagawa, Masashi Yanae, Junji Tsurutani, Kaori Tane, Yoshiyuki Morishima, Shin-ichiro Fujimoto, Kimiko Fujiwara, Shozo Nishida, Yasutaka Chiba, Shintaro Takao, Masanobu Tsubaki, Yoshifumi Komoike

المصدر: Journal of Bone Oncology, Vol 8, Iss C, Pp 18-22 (2017)
Journal of Bone Oncology

مصطلحات موضوعية: 0301 basic medicine, Oncology, Retrospective cohort study, medicine.medical_specialty, lcsh:Diseases of the musculoskeletal system, ER, estrogen receptor, MBC, metastatic breast cancer, SRE, skeletal related adverse event, Systemic therapy, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, b-MBC, bone-metastasized breast cancer, Internal medicine, medicine, HER2, human epidermal growth factor receptor 2, Adverse effect, Zoledronic acid, TN, triple-negative, business.industry, Medical record, HR, hormone receptor, Bone metastasis, BP, bisphosphonate, Symptomatic skeletal events, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Metastatic breast cancer, Surgery, CI, confidence interval, OR, odds ratio, PgR, progesterone receptor, 030104 developmental biology, 030220 oncology & carcinogenesis, SSE, symptomatic skeletal event, ZA, zoledronic acid, lcsh:RC925-935, business, Research Paper, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f66a1bac20cfb6606a9e4ddb03d2fc3Test
http://www.sciencedirect.com/science/article/pii/S2212137417300647Test

المؤلفون: Haruko Takuwa, Wakako Tsuji, Fumiaki Yotsumoto

المصدر: International Journal of Surgery Case Reports

مصطلحات موضوعية: Oncology, medicine.medical_specialty, MBC, metastatic breast cancer, FISH, fluorescence in situ hybridization, Disease, Systemic therapy, Article, Termination of therapy, 03 medical and health sciences, 0302 clinical medicine, Clinical complete response, Breast cancer, Internal medicine, medicine, Adjuvant therapy, T, trastuzumab emtansine, Multidisciplinary therapy, HER2, human epidermal growth factor receptor 2, 030212 general & internal medicine, Adverse effect, skin and connective tissue diseases, Cardiotoxicity, business.industry, cCR, clinical complete response, LHRH-a, luteinizing hormone-releasing hormone agonist, medicine.disease, Metastatic breast cancer, CT, computed tomography, PTX, paclitaxel, 030220 oncology & carcinogenesis, Anti-HER2 therapy, Surgery, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d575b4fb05261fdd1807011f600c8598Test
https://pubmed.ncbi.nlm.nih.gov/30343261Test

المؤلفون: John W.M. Martens, Wendy Onstenk, Jaco Kraan, John A. Foekens, Caroline M. Seynaeve, Paul Hamberg, Anja Brouwer, Stefan Sleijfer, Ngoc M. Van, Agnes Jager, Felix E. de Jongh, Anieta M. Sieuwerts, Nick Beije, Luc Dirix

المساهمون: Medical Oncology

المصدر: Neoplasia, 18(11), 647-653. Neoplasia Press
Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 18, Iss 11, Pp 647-653 (2016)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Cancer Research, medicine.medical_specialty, Original article, ER, estrogen receptor, MBC, metastatic breast cancer, Receptor, ErbB-2, medicine.medical_treatment, Estrogen receptor, Breast Neoplasms, CTC, circulating tumor cell, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Circulating tumor cell, SDG 3 - Good Health and Well-being, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Biomarkers, Tumor, Endocrine system, Humans, HER2, human epidermal growth factor receptor 2, PFR6months, progression-free-rate after 6 months, skin and connective tissue diseases, neoplasms, Aged, Aged, 80 and over, Chemotherapy, business.industry, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Neoplastic Cells, Circulating, Prognosis, Primary tumor, Metastatic breast cancer, 030104 developmental biology, Treatment Outcome, Receptors, Estrogen, 030220 oncology & carcinogenesis, Cohort, Female, business, PT, primary tumor

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d4fbb5219b9c6cf6089a65ce61d0c78Test
https://pure.eur.nl/en/publications/8edc9b57-5cb4-4e3c-8a17-9a2de6d48010Test